Published in Clinical Trials Week, March 15th, 2010
In making the announcement today, Sunridge International's CEO, G. Richard Smith, said that the SFDA approval marked a major step forward for the company which would, hopefully, bring with it added relief to the glaucoma sufferers in China.
"Our exclusive distributors, Beijing Vision World Trading Co, have informed us that they have received all necessary government documentation approving PNT as a medical treatment for glaucoma and ocular hypertension, as well...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2010-03-15)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.